CEBPA and acute myeloid leukemia: However, ATP1B1 shows only a trend toward lower expression in CN-AML patients with NPM1 mutation, as well as a slight trend toward higher expression in patients with single or double CEBPA mutation, which is not consistent with the known prognostic role of CEBPA mutations.